Open access
Sep 2026
Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.
The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T-cell expansion post-infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-ce...
Brydon Panozzo, S. Robinson, A. Minson et al.
· British Journal of Haematolo... · 0 citations